Micromet AG
Micromet AG is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Micromet AG.
Micromet AG is a company.
Key people at Micromet AG.
Micromet AG, later known as Micromet, Inc., was a biopharmaceutical company that developed innovative antibody-based therapies, primarily for cancer treatment, using its proprietary BiTE® (Bispecific T-cell Engager) platform. This technology creates antibodies that activate a patient's T cells to target and eliminate cancer cells.[1][2][3][5][6] The company served patients with hematological malignancies like acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL), as well as solid tumors and inflammatory diseases, addressing unmet needs in immunotherapy by offering a novel mechanism distinct from traditional monoclonal antibodies.[2][3][5][6] Its lead candidate, blinatumomab, reached Phase 3 for blood cancers, driving significant growth that culminated in a $1.2 billion acquisition by Amgen in 2012.[1][2][3][4]
Micromet originated as a spinout from the immunology department of Munich University in the early 1990s, formally incorporating as Micromet AG in 1998 in Germany.[1] It began focused on cancer diagnostics before pivoting to therapeutic antibodies amid the rise of companies like Genmab and Medarex.[1] Backed by top venture capitalists including Abingworth, it raised about $60 million in private rounds from 1996-2001, initially advancing assets like MT201.[1][4] Funding challenges arose as lead molecules stalled pre-proof-of-concept, leading to a 2006 reverse merger with U.S. public company CancerVax, providing $30 million in cash and Nasdaq listing as Micromet, Inc., with R&D in Munich and HQ in Rockville, MD.[1][2][4][6]
Micromet rode the early 2000s immunotherapy wave, pioneering BiTE technology during a shift from passive monoclonal antibodies to active T-cell engagers, aligning with booming demand for targeted cancer therapies in a market projected to grow from $18 billion in 2008 to $45 billion by 2018 at 9.8% CAGR.[1][6] Timing was ideal post-Abgenix/Medarex successes, as Big Pharma sought differentiated platforms amid patent cliffs and rising solid tumor challenges.[1][2] It influenced the ecosystem by validating bispecific antibodies—Amgen's 2012 acquisition integrated BiTE into its oncology portfolio, with blinatumomab (now Blincyto) FDA-approved in 2014 for ALL, inspiring rivals like Roche's bispecifics and cementing Munich as a biotech hub.[1][2][3]
Post-acquisition, Micromet's legacy endures through Amgen's Munich R&D center and Blincyto's commercialization, with BiTE tech expanding to new indications and partners deriving milestone/royalty value.[1][2] Emerging trends like next-gen bispecifics, ADCs, and combo immunotherapies will amplify its influence, as solid tumor applications (e.g., solitomab Phase 1) evolve amid AI-driven antibody design. Micromet's trajectory—from university spinout to $1.2B exit—exemplifies how platform innovation in blood cancers can redefine oncology, powering Amgen's fight against unmet needs that persist today.[1][2][3]
Key people at Micromet AG.
